Idera Pharmaceuticals is providing an update on its tilsotolimod clinical development program and a corporate outlook for 2020.
Idera Pharmaceuticals (NASDAQ:IDRA) is providing an update on its tilsotolimod clinical development program and a corporate outlook for 2020.
As quoted in the press release:
“We made tremendous progress last year with the tilsotolimod clinical development program, and we are positioned well going into this pivotal year,” stated Vincent Milano, Idera’s Chief Executive Officer. “Our ILLUMINATE-301 registrational trial of tilsotolimod in anti-PD-1 refractory metastatic melanoma is enrolling at a rate that dramatically exceeded our expectations. We expect to complete enrollment this quarter, setting up the possibility of data before the end of this year. We believe the rapid enrollment in this randomized trial is a testament to the critical unmet need for this patient group as well as to the growing appreciation from global investigators for both intratumoral administration and the mechanism of action of tilsotolimod.”
Continued Milano, “We also will add to the overall body of clinical evidence for tilsotolimod with additional data readouts expected in the second quarter. Final analysis of ILLUMINATE-204 will include median overall survival (OS) for the first time, and ILLUMINATE-206 will provide safety and preliminary efficacy in microsatellite-stable colorectal cancer (MSS-CRC) as a triple combination of ipilimumab, nivolumab and tilsotolimod in this immunorefractory indication.”